Beth Seidenberg is a general partner at Kleiner Perkins, a venture capital firm. She has been actively investing in biotechnology and healthcare companies. Beth Seidenberg has demonstrated her strong commitment to advancing oncology research and innovation through strategic investments in a series of prominent companies. Her investment portfolio includes Arsenal Bio, TESARO (acquired by GSK), Sagimet Biosciences, Flexus Biosciences (acquired by Bristol-Myers Squibb), ARMO BioSciences (acquired by Lilly), Tmunity (acquired by Kite), Epizyme (acquired by Ipsen), and Atara Biotherapeutics. These investments underscore her dedication to driving advancements in cancer therapies and shaping the future of oncology treatments.